NewsBenzinga据报道，GSK 的 Jemperli 单药治疗在 II 期 AZUR-1 MSI-H/dMMR 直肠癌试验中显示出总体一致的安全性，严重不良反应发生率为 20%，停药率为 3%，同时完全缓解率达 76% 据报道，GSK 的 Jemperli 单药治疗在 II 期 AZUR-1 MSI-H/dMMR 直肠癌试验中显示出总体一致的安全性，严重不良反应发生率为 20%，停药率为 3%，同时完全缓解率达 76% Benzinga 2026.10.26 07:32 (GMT+0) Open on Benzinga Other news BMO Capital Initiates Coverage On FirstEnergy with Outperform Rating, Announces Price Target of $50 Why Surgery Partners Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket Support for semiconductor stocks could be as much as 15% lower than current levels, says Morgan Stanley Weekly Market Pulse: Where The Puck Will Be Amcor’s Quarterly Earnings Preview: What You Need to Know Apple's Design Team Didn't Want Touchscreen Macs, But Tim Cook and John Ternus Had Other Ideas: Report
Support for semiconductor stocks could be as much as 15% lower than current levels, says Morgan Stanley
Apple's Design Team Didn't Want Touchscreen Macs, But Tim Cook and John Ternus Had Other Ideas: Report
